Rentosertib: What Do Aging Clocks Reveal

What did the rentosertib aging clock analysis find?

Published September 7 in Nature Biotechnology, the analysis examined blood proteins from a subset of participants in an earlier clinical trial. Proteomic clocks use protein patterns to estimate biological age or aging-related risk. Treatment-associated changes generally pointed toward younger predicted profiles. [Proteomic clock study](https://www.nature.com/articles/s41587-026-03286-y)

However, the clocks could not separate effects on aging from changes caused by treating lung disease. Participants were selected from trial completers with available samples, limiting generalizability. Agreement across models strengthens the rationale for investigation, but does not establish a whole-body anti-aging effect. [Study findings and limitations](https://www.nature.com/articles/s41587-026-03286-y)

How is rentosertib being tested for pulmonary fibrosis?

Idiopathic pulmonary fibrosis causes progressive lung scarring. Rentosertib targets TNIK, a protein involved in signaling pathways implicated in fibrosis. The original randomized, double-blind phase 2a trial assigned 71 participants to three oral dosing regimens or placebo. Its primary endpoint measured adverse events; lung-function changes were secondary outcomes. [Original clinical trial](https://www.nature.com/articles/s41591-025-03743-2)

The highest-dose group showed an encouraging average change in forced vital capacity, a measure of how much air someone can forcefully exhale. However, the small study was insufficient to establish durable benefit. Liver toxicity and diarrhea were among the events leading to treatment discontinuation. Larger, longer trials need to clarify effectiveness, safety and interactions with other antifibrotic medicines before the findings can support treatment decisions. [Efficacy and safety results](https://www.nature.com/articles/s41591-025-03743-2)

Can a lower biological age score prove that a drug works?

The FDA distinguishes biomarkers, which indicate biological processes or responses to treatment, from clinical outcomes reflecting how patients feel, function or survive. Some biomarkers become validated surrogate endpoints when evidence shows that treatment-induced changes reliably predict a specific clinical benefit. That relationship must be established for the intended setting. [FDA explanation of biomarkers and surrogate endpoints](https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints)

Applied to this research, the implication is that aging-clock improvements should guide further testing rather than determine clinical success. Future studies would need to connect such changes with meaningful outcomes and assess harms alongside benefits. A favorable laboratory signal cannot capture every effect of a medicine; even established surrogate endpoints can mislead when a treatment has additional harmful actions. [FDA discussion of surrogate limitations](https://www.fda.gov/about-fda/innovation-fda/fda-facts-biomarkers-and-surrogate-endpoints)